Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96G74
UPID:
OTUD5_HUMAN
Alternative names:
Deubiquitinating enzyme A
Alternative UPACC:
Q96G74; B4DGG7; G5E9D7; Q4KMN9; Q8N6T5; Q9H650; Q9H9U0; Q9NT65
Background:
OTU domain-containing protein 5, also known as Deubiquitinating enzyme A, plays a pivotal role in the innate immune system by regulating type I interferon production through TRAF3 deubiquitination. Its enzymatic activity extends to cleaving 'Lys-48'-, 'Lys-63'-, and 'Lys-11'-linked polyubiquitin chains, crucial for neuroectodermal differentiation and the stability of key chromatin regulators.
Therapeutic significance:
Linked to Multiple congenital anomalies-neurodevelopmental syndrome, X-linked, understanding OTU domain-containing protein 5's function could unveil novel therapeutic avenues.